SARS-Cov-2

Treatment with Paxlovid significantly reduced the duration and severity of SARS-CoV-2 infection among high-risk patients while also reducing health care utilization and severe outcomes, according to a study.

I initially became hooked on ID when I was a medical student rounding on ID service and was evaluating a person with pneumonia who had just expectorated purulent sputum.

Researchers presented data at IDWeek showing that socioeconomic vulnerability and race can negatively impact vaccine uptake.

Children who have multiple long-term conditions are as almost three times more likely to die after COVID-19 compared with children who do not, according to data published in Journal of the Royal Society of Medicine.

Higher disease activity and medication reduction at COVID-19 vaccination increase the risk for subsequent flares in patients with rheumatic and musculoskeletal diseases, according to data published in Annals of the Rheumatic Diseases.

Patients with autoimmune or inflammatory rheumatic diseases living in rural areas demonstrate a 24% higher mortality risk after SARS-CoV-2 infection vs. those in urban areas, according to data published in Arthritis Care & Research.

Among patients with systemic autoimmune disease in a large, real-world cohort, 29.8% reported long COVID, with frequent impacts to quality of life, following infection, according to data published in The Journal of Rheumatology.

Nearly 10% of women infected with SARS-CoV-2 during pregnancy had post-acute sequelae 6 or more months later, according to results of the RECOVER-Pregnancy study published in Obstetrics & Gynecology.

A 15-day course of Paxlovid demonstrated no significant benefit for patients with post-acute sequelae of SARS-CoV-2 infection, according to data published in JAMA Internal Medicine.

Approximately 25% of patients with COVID-19 who are immunocompromised remain positive for the disease 21 days or more from initial onset, according to data published in The Lancet Microbe.